Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Recombinant human TS enzyme|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunoprecipitation (IP)||2 µg/ml|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13512 targets Thymidylate Synthase in ELISA, FACS, IF, IP, and WB applications and shows reactivity with Human samples.
The MA5-13512 immunogen is recombinant human TS enzyme.
Thymidylate Synthase (TS) (EC 22.214.171.124) converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis. TS is a critical target for the fluoropyrimidines, an important group of antineoplastic drugs that are widely used in the treatment of solid tumors. Both 5-FU and fluorodeoxyuridine are converted in tumor cells to FdUMP which inactivates TS by formation of a ternary covalent complex in the presence of the folate cofactor 5,10-methylenetetrahydrofolate. Expression of TS protein is associated with response to 5-fluorouracil (5-FU) in human colorectal, gastric, head and neck, and breast carcinomas.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
MA5-13512 was used in immunohistochemistry - paraffin section to identify biomarkers relevant to treatment outcomes in gastric cancer patients receiving adjuvant S-1 chemotherapy.
|Kim JY,Shin E,Kim JW,Lee HS,Lee DW,Kim SH,Lee JO,Kim YJ,Kim JH,Bang SM,Ahn SH,Park DJ,Lee JS,Lee JS,Kim HH,Lee KW||PloS one (10:null)||2015|
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
MA5-13512 was used in immunohistochemistry - paraffin section to evaluate thymidylate synthase and microsatellite instability in colorectal cancer
|Bendardaf R,Lamlum H,Ristamäki R,Korkeila E,Syrjänen K,Pyrhönen S||Acta oncologica (Stockholm, Sweden) (47:1046)||2008|
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
MA5-13512 was used in immunohistochemistry - paraffin section to study the value of ERCC1 expression in predicting chemoradiation resistance and poor outcome in oesophageal cancer
|Kim MK,Cho KJ,Kwon GY,Park SI,Kim YH,Kim JH,Song HY,Shin JH,Jung HY,Lee GH,Choi KD,Kim SB||European journal of cancer (Oxford, England : 1990) (44:54)||2008|
|Not Applicable||Not Cited||
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
MA5-13512 was used in immunohistochemistry - paraffin section to study the role of high thymidylate synthase expression in colorectal cancer with microsatellite instability
|Ricciardiello L,Ceccarelli C,Angiolini G,Pariali M,Chieco P,Paterini P,Biasco G,Martinelli GN,Roda E,Bazzoli F||Clinical cancer research : an official journal of the American Association for Cancer Research (11:4234)||2005|
Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
MA5-13512 was used in immunohistochemistry (paraffin) to use molecular profiling to assess expression of biomarkers of operable gastric adenocarcinoma being treated with epirubicin, cisplatin, and 5-fluorouracil.
|Miura JT,Johnston FM,Thomas J,George B,Eastwood D,Tsai S,Christians KK,Turaga KK,Gamblin TC||Journal of surgical oncology (110:302)||2014|
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
MA5-13512 was used in immunohistochemistry to examine the use of thymidylate synthase and folylpolyglutamate synthase as biomarkers to predict the of outcome after pemetrexed in patients.
|Lustgarten DE,Deshpande C,Aggarwal C,Wang LC,Saloura V,Vachani A,Wang LP,Litzky L,Feldman M,Creaney J,Nowak AK,Langer C,Inghilleri S,Stella G,Albelda SM||Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (8:469)||2013|
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.
MA5-13512 was used in western blot to investigate the relationship between folate and apoptosis using melanoma cells.
|Giudice S,Benassi L,Bertazzoni G,Veratti E,Morini D,Azzoni P,Costi MP,Venturelli A,Pirondi S,Seidenari S,Magnoni C||Investigational new drugs (30:1484)||2012|
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
MA5-13512 was used in immunohistochemistry - paraffin section to investigate the prognostic effectiveness of thymidylate synthase in the chemotherapy of malignant pleural mesothelioma
|Righi L,Papotti MG,Ceppi P,Billè A,Bacillo E,Molinaro L,Ruffini E,Scagliotti GV,Selvaggi G||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (28:1534)||2010|
Translational repression of thymidylate synthase by targeting its mRNA.
MA5-13512 was used in western blot to elucidate how Hoechst 33258 reduces thymidylate synthase
|Garg D,Beribisky AV,Ponterini G,Ligabue A,Marverti G,Martello A,Costi MP,Sattler M,Wade RC||Nucleic acids research (41:4159)||2013|
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
MA5-13512 was used in western blot to report on a phase II clinical trial of modified FOLFOX-6 chemotherapy in advanced gastric cancer
|Keam B,Im SA,Han SW,Ham HS,Kim MA,Oh DY,Lee SH,Kim JH,Kim DW,Kim TY,Heo DS,Kim WH,Bang YJ||BMC cancer (8:null)||2008|
Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.
MA5-13512 was used in western blot to investigate the efficacy of pemetrexed as a multitargeted antifolate drug against osteosarcoma cell lines
|Bodmer N,Walters DK,Fuchs B||Pediatric blood and cancer (50:905)||2008|
Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.
MA5-13512 was used in western blot to evaluate autoantibodies against thymidylate synthase as a biomarker for cancer progression and therapeutic effectiveness
|Shebzukhov YV,Koroleva EP,Khlgatian SV,Lagarkova MA,Meshcheryakov AA,Lichinitser MR,Karbach J,Jager E,Kuprash DV,Nedospasov SA||Immunology letters (100:88)||2005|
The anticytomegaloviral activity of raltitrexed is abrogated in quiescent mouse fibroblasts that overexpress thymidylate synthase.
MA5-13512 was used in western blot to investigate the effect of thymidylate synthase on the anticytomegaloviral activity of raltitrexed
|Gribaudo G,Riera L,Lembo D,De Andrea M,Johnson LF,Landolfo S||Virus research (73:57)||2001|
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
MA5-13512 was used in immunohistochemistry to study the prognostic value of ERCC1 and thymidylate synthase expression in malignant pleural mesothelioma
|Kao SC,Lee K,Klebe S,Henderson D,McCaughan B,Vardy J,Clarke S,van Zandwijk N||Clinical lung cancer (14:164)||2013|
Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
MA5-13512 was used in immunohistochemistry to study the prognostic significance of Bax, ERCC1, and TS in advanced gastric cancer patients treated with FOLFOX palliative chemotherapy
|Jeong SH,Han JH,Kim JH,Ahn MS,Hwang YH,Lee HW,Kang SY,Park JS,Choi JH,Lee KJ,Sheen SS,Lim HY||Digestive diseases and sciences (56:131)||2011|
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
MA5-13512 was used in immunohistochemistry to study the association of Topoisomerase I with improved outcome in patients with resected colorectal cancer treated with irinotecan adjuvant chemotherapy
|Kostopoulos I,Karavasilis V,Karina M,Bobos M,Xiros N,Pentheroudakis G,Kafiri G,Papakostas P,Vrettou E,Fountzilas G||BMC cancer (9:null)||2009|
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
MA5-13512 was used in immunohistochemistry to study the efficacy of combined cetuximab and modified FOLFOX6 treatment in a phase II gastric cancer trial
|Han SW,Oh DY,Im SA,Park SR,Lee KW,Song HS,Lee NS,Lee KH,Choi IS,Lee MH,Kim MA,Kim WH,Bang YJ,Kim TY||British journal of cancer (100:298)||2009|
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.
MA5-13512 was used in immunohistochemistry to examine the prognostic significance of thymidylate synthase in stage I nonsmall-cell lung cancer
|Zheng Z,Li X,Schell MJ,Chen T,Boulware D,Robinson L,Sommers E,Bepler G||Cancer (112:2765)||2008|
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
MA5-13512 was used in immunohistochemistry to investigate the influence of chemotherapy on the function of specific cytotoxic T lymphocytes
|Correale P,Del Vecchio MT,La Placa M,Montagnani F,Di Genova G,Savellini GG,Terrosi C,Mannucci S,Giorgi G,Francini G,Cusi MG||Journal of immunotherapy (Hagerstown, Md. : 1997) (31:132)||2008|
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).
MA5-13512 was used in immunohistochemistry to study the prognostic value of thymidylate synthetase, ubiquitin specific protease 10 and survivin in glioblastoma multiforme
|Grunda JM,Nabors LB,Palmer CA,Chhieng DC,Steg A,Mikkelsen T,Diasio RB,Zhang K,Allison D,Grizzle WE,Wang W,Gillespie GY,Johnson MR||Journal of neuro-oncology (80:261)||2006|
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
MA5-13512 was used in immunohistochemistry to evaluate a thymidylate synthase-directed polyepitopic peptide vaccine against tumors
|Correale P,Del Vecchio MT,Di Genova G,Savellini GG,La Placa M,Terrosi C,Vestri M,Urso R,Lemonnier F,Aquino A,Bonmassar E,Giorgi G,Francini G,Cusi MG||Journal of the National Cancer Institute (97:1437)||2005|
Role of biological markers in the clinical outcome of colon cancer.
MA5-13512 was used in immunohistochemistry to study the prognostic markers for colon cancer
|Nanni O,Volpi A,Frassineti GL,De Paola F,Granato AM,Dubini A,Zoli W,Scarpi E,Turci D,Oliverio G,Gambi A,Amadori D||British journal of cancer (87:868)||2002|
Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).
MA5-13512 was used in immunocytochemistry to investigate the effect of fluorouracil on the expression of thymidylate synthase and MRP
|Jin J,Huang M,Wei HL,Liu GT||World journal of gastroenterology (8:1029)||2002|
Thymidylate synthase; TS; TSase
HST422; OK/SW-cl.29; TMS; TS; TYMS